ArticleOncogene2008
In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- MYC is in the CARDs: CBM complexes coordinate immune and MYC-dependent cellular function.Frontiers in molecular medicine · 2025Article
- Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.Advances in biological regulation · 2019Review
- Role of autotaxin in cancer stem cells.Cancer metastasis reviews · 2018Review
- Review
- New insights into signalling-pathway alterations in rhabdomyosarcoma.British journal of cancer · 2015Review
- Lysophospholipid receptor nomenclature review: IUPHAR Review 8.British journal of pharmacology · 2014Review
- Article
- Mitochondrial alteration in malignantly transformed human small airway epithelial cells induced by α-particles.International journal of cancer · 2013Article
- Mitigation of radiation injury by selective stimulation of the LPA(2) receptor.Biochimica et biophysica acta · 2013Article
- Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.Biochimica et biophysica acta · 2013Review
- Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.Molecular pharmacology · 2012Article
- Chemical evolution of autotaxin inhibitors.Chemical reviews · 2012Review
- Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.International journal of oncology · 2012Article
- Microenvironments dictating tumor cell dormancy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2012Review
- ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Review
- Insights into autotaxin: how to produce and present a lipid mediator.Nature reviews. Molecular cell biology · 2011Review
- Structural basis of substrate discrimination and integrin binding by autotaxin.Nature structural & molecular biology · 2011Article
- LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor.PloS one · 2011Article
- CARMA3: A novel scaffold protein in regulation of NF-κB activation and diseases.World journal of biological chemistry · 2010Article
- Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
c-Myc drives uncontrolled cell proliferation in various human cancers. However, in mouse embryo fibroblasts (MEFs), c-Myc also induces apoptosis by activating the p19Arf tumor suppressor pathway. Tbx2, a transcriptional repressor of p19Arf, can collaborate with c-Myc by suppressing apoptosis. MEFs overexpressing c-Myc and Tbx2 are immortal but not transformed. We have performed an unbiased genetic screen, which identified 12 oncogenes that collaborate with c-Myc and Tbx2 to transform MEFs in vitro. One of them encodes the LPA2 receptor for the lipid growth factor lysophosphatidic acid (LPA). We find that LPA1 and LPA4, but not LPA3, can reproduce the transforming effect of LPA2. Using pharmacological inhibitors, we show that the in vitro cell transformation induced by LPA receptors is dependent on the Gi-linked ERK and PI3K signaling pathways. The transforming ability of LPA1, LPA2 and LPA4 was confirmed by tumor formation assays in vivo and correlated with prolonged ERK1/2 activation in response to LPA. Our results reveal a direct role for LPA receptor signaling in cell transformation and tumorigenesis in conjunction with c-Myc and reduced p19Arf expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.